Insys Therapeutics (INSY) Misses Q2 EPS by 1c

Insys Therapeutics (NASDAQ: INSY) reported Q2 EPS of $0.06, $0.01 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $67.1 million versus the consensus estimate of $66.9 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• Private Bancorp of America, Inc. (PBAM) Tops Q2 EPS by 26c
• Alcoa (AA) Misses Q2 EPS by 20c